(Q38192156)

30 August 2017

1 reference

title

A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer (English)

1 reference

30 August 2017

1 reference

1

1 reference

30 August 2017

Ian M Thompson

2

1 reference

30 August 2017

Eric Klein

series ordinal

3

1 reference

30 August 2017

Peter R Carroll

series ordinal

4

1 reference

30 August 2017

Peter T Scardino

series ordinal

5

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 March 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

83

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

592-596

1 reference

Evaluating the yield of medical tests

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Assessing the incremental value of diagnostic and prognostic markers: a review and illustration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Assessing the performance of prediction models: a framework for traditional and novel measures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened P

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Point: Impact of prostate-specific antigen velocity on management decisions and recommendations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Prostate-specific antigen levels as a predictor of lethal prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Prostate-specific antigen velocity and prostate cancer gleason grade and stage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Prostate-specific Antigen Velocity: New Methods, Same Results, Still No Evidence of Clinical Utility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.09.075

10.1016/J.UROLOGY.2013.09.075

7 January 2021

Identifiers

DOI

1 reference

30 August 2017

1 reference